RYZ101

Phase 3Small molecule

RRayzeBio, Inc.

RYZ101 is one of 50 small molecule programs targeting Metastatic Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Breast CancerActive, not recruiting

ES-SCLCRecruiting

GEP-NETRecruiting

Metastatic Breast CancerPreclinical

Active, not recruiting

ES-SCLCPhase 1

Recruiting

GEP-NETPhase 3

Recruiting

Competition

Competitive Landscape

48 competitors in Metastatic Breast Cancer

#DrugCompanyPhaseTrials

Kisqali

Novartis

Approved

6 2

Femara

Novartis

Approved

2 3

Nolvadex

AstraZeneca

Approved

1 4

Faslodex

FFresenius Kabi USA, LLC

Approved

8 5

Arimidex

IIstituto Clinico Humanitas

Approved

2 6

Zoladex

TTerSera Therapeutics LLC

Approved

1 7

Ibrance

Pfizer

Phase 3

6 8

Fotivda

Roche

Phase 3

2 9

Aromasin

Pfizer

Phase 3

1 10

Taxol

Teva

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

GEP-NET

NCT05477576

Q1 2029

Phase 1Recruiting

ES-SCLC

NCT05595460

Q4 2033

PreclinicalActive, not recruiting

Metastatic Breast Cancer

NCT06590857

Clinical

Trials by Indication[1]

GEP-NET1 trial

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting·RRayzeBio, Inc.·Phase 3·NCT05477576·288 enrolled

ES-SCLC1 trial

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Recruiting·RRayzeBio, Inc.·Phase 1·NCT05595460·49 enrolled

Metastatic Breast Cancer1 trial

Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1).

Active, not recruiting·RRayzeBio, Inc.·Preclinical·NCT06590857·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for RYZ101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RYZ101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RYZ101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RayzeBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRayzeBio, Inc.

RYZ101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2029

Q4 2033

Trials by Indication[1]

GEP-NET1 trial

ES-SCLC1 trial

Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News